Novel Drosophila model for parkinsonism by targeting phosphoglycerate kinase

https://doi.org/10.1016/j.neuint.2020.104816Get rights and content

Highlights

  • Pan neuron-specific Pgk knockdown decreases ATP level and increases ROS level in the larval CNS.

  • DA neuron-specific knockdown of Pgk causes locomotor defects in adult stages.

  • DA neuron-specific knockdown of Pgk induces progressive DA neurons loss in the PPM1/2 cluster.

  • DA neuron-specific knockdown of Pgk decreases dopamine levels in the CNS.

Abstract

Patients with Parkinson's disease (PD) show a common progressive neurodegenerative movement disorder characterized by rigidity, tremors, postural instability, and bradykinesia due to the loss of dopaminergic neurons in the substantia nigra, and is often accompanied by several non-motor symptoms, called parkinsonism. Several lines of recent evidence support the hypothesis that mutations in the gene encoding phosphoglycerate kinase (PGK) play an important role in the PD mechanism. PGK is a key enzyme in the glycolytic pathway that catalyzes the reaction from 1,3-diphosphoglycerate to 3-phosphoglycerate. We herein established a parkinsonism model targeting Drosophila Pgk. Dopaminergic (DA) neuron-specific Pgk knockdown lead to locomotive defects in both young and aged adult flies and was accompanied by progressive DA neuron loss with aging. Pgk knockdown in DA neurons decreased dopamine levels in the central nervous system (CNS) of both young and aged adult flies. These phenotypes are similar to the defects observed in human PD patients, suggesting that the Pgk knockdown flies established herein are a promising model for parkinsonism. Furthermore, pan-neuron-specific Pgk knockdown induced low ATP levels and the accumulation of reactive oxygen species (ROS) in the CNS of third instar larvae. Collectively, these results indicate that a failure in the energy production system of Pgk knockdown flies causes locomotive defects accompanied by neuronal dysfunction and degeneration in DA neurons.

Introduction

Parkinson's disease (PD) is a common progressive neurodegenerative movement disorder characterized by rigidity, tremors, postural instability, and bradykinesia due to the loss of dopaminergic (DA) neurons in the substantia nigra, and is often accompanied by several non-motor symptoms, including autonomic dysfunction and dementia, called parkinsonism. The etiology of PD remains unknown. However, in the past 2 decades, clinical and experimental evidence on PD has collectively implicated three major pathogenic mechanisms: (i) oxidative stress and defective energy conservation, (ii) impaired protein turnover, and (iii) disrupted synaptic and endosomal vesicle and protein trafficking and recycling (Obeso et al., 2017).

The case for oxidative stress and defective energy conservation due to mitochondrial dysfunction in at least part of the pathogenesis of PD has been becoming increasingly persuasive. This is supported by several mitochondrial toxins of Complex I blockers, including rotenone and MPP + that are commonly used to create PD animal models, since they induce parkinsonism in humans and animals (Bove and Perier, 2012; Panov et al., 2005). The crucial role of mitochondria in PD was also suggested by a number of studies demonstrating that Parkin and PINK1, the genes associated with familial PD, are relevant for mitochondrial homeostasis. Moreover, another PD-related gene, DJ-1 is known to translocate from the nucleus to the mitochondrial matrix and intramembrane space under oxidative stress conditions, suggesting its role as an oxidative stress sensor (Grunewald et al., 2019; Morais et al., 2009; Zhang et al., 2005). Although the glycolysis system that is the upstream pathway of mitochondrial energy production in the cytosol has not attracted much attention in this field, recent studies reported dysregulated glycolysis in postmortem brain tissues and peripheral blood mononuclear cells from sporadic PD (Dunn et al., 2014; Liu et al., 2016) as well as in cultured cells with the ablation of Parkin (Dunn et al., 2014).

Phosphoglycerate kinase (PGK) encoded by PGK-1 (OMIM #311800), which maps to the X chromosome in humans, is a key enzyme in the glycolytic pathway catalyzing the conversion from 1.3-diphosphoglycerate to 3-phosphoglycerate. PGK deficiency (OMIM #300653) causes X-linked recessive hereditary chronic hemolytic anemia and myopathy due to insufficient energy production in red blood cells and muscles (Beutler, 2007). The disease has been known to be occasionally accompanied by levodopa-responsive parkinsonism (Morales-Briceno et al., 2019; Sotiriou et al., 2010; Virmani et al., 2014). The function of the gene has recently received growing attention in the PD field, because pharmacological enhancement of PGK activity successfully attenuated the PD phenotypes in several animal models (Cai et al., 2019). We also reported that parkinsonism was observed not only in a patient with PGK deficiency, but also in a heterozygous carrier of the disease who was originally considered to be asymptomatic (Sakaue et al., 2017). Noteworthy, PD symptoms observed in the heterozygous carrier in our case report was indistinguishable from that in typical PD (Sakaue et al., 2017). PGK-1 is located within the confirmed susceptibility locus for familial PD known as PARK12, implying that this gene might be the causative gene or one of the causative genes of PARK12. Therefore, we hypothesize that an insufficiency in PGK-1 expression may lead to the degeneration of DA neurons and confer susceptibility to PD. To provide supporting evidence for our hypothesis, we herein investigated the phenotypes of fly models with the knockdown of the Drosophila PGK-1 homologue, the Pgk gene. Drosophila has been used as a model organism to study human neurodegenerative diseases including PD (Chow and Reiter, 2017). Drosophila contains homologues of many PD-associated genes (Botella et al., 2009; Whitworth, 2011). The cell lineage of DA neurons during development has been clarified and DA neuron clusters in the central nervous system (CNS) may be easily identified in the adult stages (Botella et al., 2008). The data obtained from Drosophila Pgk knockdown flies indicate that a failure in the energy production system of Pgk knockdown flies causes locomotive defects accompanied by neuronal dysfunction and degeneration in DA neurons.

Section snippets

Fly stocks

Flies were reared on standard food containing 0.65% agar, 10% glucose, 4% dry yeast, 5% cone flour, and 3% rice bran at 25 °C (Suda et al., 2019). w; UAS-PgkIR1123-1452; + (110081) was obtained from the Vienna Drosophila Resource Center (VDRC). The fly lines carrying w; +; UAS-PgkIR1810-1830/+(35220), w; P[ple-GAL4.F]3 (8848), w; P[UAS-Sod1]12.1 (33605) and y1 w; P[nSyb-GAL4.S]3 (51635) were obtained from the Bloomington Drosophila Stock Center (BDSC) at Indiana University. The RNAi of these

Amino acid sequence comparison of human PGK1 and Drosophila Pgk

Drosophila Pgk (CG3127) was identified as a single homologue by a Blast search with human PGK1. By using FASTA and BLAST, the amino acid (aa) sequence of Drosophila Pgk retrieved from UniProt was compared with aa sequence of human PGK1. This comparison showed high conservation between Drosophila Pgk and human PGK1, with 63.5% identity and 93.5% similarity. Human PGK1 encodes a protein consisting of 417 aa, while Drosophila Pgk encodes 415 aa (Fig. 1). The regions responsible for substrate

Discussion

The DA neuron-specific knockdown of Pgk induced locomotive defects in both young and aged adult flies. In aged flies, the number of DA neurons in PPM1/2 clusters was decreased. Although the number of DA neurons in the examined clusters was not decreased basically in young adult flies, dopamine levels were reduced in young and aged adult flies. Therefore, dopamine levels appear to correlate with locomotive ability. Drosophila models targeting auxilin, a homologue of Cyclin-G-associated kinase (

Funding

This research was partially supported by the JSPS Core-to-Core Program, Asia-Africa Science Platforms to MY and HY, and JSPS KAKENHI Grant Number JP19K06659 to MY. JSPS KAKENHI 18K07506, a Dainippon Sumitomo Pharma Research grant, and Takeda Science Foundation grant were awarded to TK.

Author contributions

JS, TK, HY, and MY conceptualized and designed the study. JS, TK, YN and MS performed experiments and analyzed data. JS, TK, HY and MY wrote the manuscript. MY, TT, and TM contributed to resources and edited the manuscript. AMH contributed the revise experiments. All authors reviewed and approved the manuscript.

Data availability statements

All of the original data are available on request.

Declaration of competing interest

The authors declare no competing interest.

Acknowledgments

We thank the Bloomington Drosophila Stock Center and Vienna Drosophila Genetic Resource Center for the fly lines. We would like to acknowledge Dr. Ryo Tanaka, Ms. Ibuki Ueoka, Mr. Tomoki Hirashima, Mr. Kojiro Suda, and all the chromosome laboratory members for their technical support, valuable discussions, and suggestions.

References (39)

  • H. Morales-Briceno et al.

    Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction

    Park. Relat. Disord.

    (2019)
  • Y. Muraoka et al.

    Genetic screening of the genes interacting with Drosophila FIG 4 identified a novel link between CMT-causing gene and long noncoding RNAs

    Exp. Neurol.

    (2018)
  • A. Panov et al.

    Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication

    J. Biol. Chem.

    (2005)
  • L. Song et al.

    Auxilin underlies progressive locomotor deficits and dopaminergic neuron loss in a Drosophila model of Parkinson's disease

    Cell Rep.

    (2017)
  • I. Ueoka et al.

    Novel Drosophila model for psychiatric disorders including autism spectrum disorder by targeting of ATP-binding cassette protein A

    Exp. Neurol.

    (2018)
  • A.J. Whitworth

    Drosophila models of Parkinson's disease

    Adv. Genet.

    (2011)
  • E. Beutler

    PGK deficiency

    Br. J. Haematol.

    (2007)
  • J.A. Botella et al.

    Modelling Parkinson's disease in Drosophila

    NeuroMolecular Med.

    (2009)
  • R. Cai et al.

    Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases

    J. Clin. Invest.

    (2019)
  • Cited by (6)

    • Impaired age-dependent increases in phosphoglycerate kinase activity in red blood cells of Parkinson's disease patients

      2021, Parkinsonism and Related Disorders
      Citation Excerpt :

      Additionally, PGK-1 is located at Xq21.1, which is included in a susceptibility locus (Xq21-Xq25) of an X-linked familial PD, PARK12 [11]. Based on these findings, we established knockdown models of Pgk, an ortholog of PGK-1, in Drosophila and found degeneration of the dopaminergic neurons, reduction of dopamine and ATP levels in the central nervous system (CNS), accumulation of reactive oxygen species in the CNS, and locomotive deficit in these lines [12]. Taking those findings together, PGK-1 is considered to be partially involved in the pathogenesis of PD.

    • E2F regulation of the Phosphoglycerate kinase gene is functionally important in Drosophila development

      2023, Proceedings of the National Academy of Sciences of the United States of America
    View full text